Richter transformation

This early-phase study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goa…

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …

This study tests a new drug called glofitamab, given with standard chemotherapy, for people with untreated Richter syndrome (an aggressive lymphoma that develops from chronic lymphocytic leukemia). The goal is to see if this combination can shrink or eliminate the cancer. About 4…

This trial tests a therapy where a person's own immune cells are modified to attack cancer cells carrying a protein called CD19. It is for adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia that has not responded to standa…

This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…

This early-phase trial tests a new injection called IASO207 for people with relapsed or refractory B-cell blood cancers. Unlike current CAR-T therapies that require removing and engineering cells in a lab, IASO207 is designed to create cancer-fighting T cells directly inside the …

This study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …

This early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the d…

This phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also chec…

This early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem …

This early-stage trial tests a new treatment called IC19/1563 for people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recogn…

This study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and…

This early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …

This phase II trial tests whether combining nemtabrutinib (a targeted drug) with pembrolizumab (an immunotherapy) can shrink tumors in 32 people with Richter transformation, an aggressive lymphoma that arises from chronic lymphocytic leukemia. Participants must have failed or be …

This phase 2 trial tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can shrink tumors in people with diffuse large B-cell lymphoma that has relapsed or become resistant. The study will enroll 36 adults and measure how many patients respond and…

This study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if …

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This study tests whether a time-limited combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) is safe and effective for people with untreated chronic lymphocytic leukemia (CLL) or Richter transformation (RT). About 60 adults with good organ function and perform…

This study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…

This early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The ther…

This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…

This study tests a personalized CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. Patients' own immune cells are collected, modified to target cancer cells, and infused back. The trial has two phases: first to find the safest dos…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) in people with Richter transformation, a rare and fast-growing lymphoma that develops from chronic lymphocytic leukemia (CLL). The goal is to control the disease and improve survival. About …

This study tests whether the drug acalabrutinib, taken as a pill, can safely prevent relapse in people with very high-risk large B-cell lymphoma after they receive cell therapy (stem cell transplant or CAR T-cells). The trial will enroll 24 adults aged 18-70. Researchers will tra…

This early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…

This study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. The goal is to see if this combo can …

This early-phase trial is testing a drug called tegavivint in about 18 people with large B-cell lymphoma that has come back or not responded to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The main goals are to find a safe dose and …

This early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …

This phase 2 trial tests the drug nivolumab (Opdivo) in 14 people with Richter's transformation, a rare and aggressive blood cancer that arises from chronic lymphocytic leukemia. The study measures how many patients respond to treatment, how long they live, and safety. All partic…

This study tests whether adding two targeted drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy can help control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be ran…

This study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effecti…

This study tests a drug called glofitamab, alone or with other medicines, in people whose chronic lymphocytic leukemia (CLL) has turned into a more aggressive cancer called Richter's transformation. About 70 adults will receive treatment to see if the cancer shrinks or disappears…

This study is for people aged 70 and older with a type of blood cancer called DLBCL. After initial chemotherapy, a blood test checks for leftover cancer DNA. If found, patients receive an extra targeted drug (mosunetuzumab) to try to clear it. The goal is to improve disease contr…

This phase 2 trial is testing whether adding the drug polatuzumab vedotin to standard chemotherapy can improve remission rates in people with Richter's transformation, an aggressive lymphoma that can develop from chronic lymphocytic leukemia (CLL). About 20 adults with confirmed …

This early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …

This early-phase trial is testing whether combining two drugs—zanubrutinib and odronextamab—is safe for people with Richter's transformation, a rare and aggressive form of blood cancer that arises from chronic lymphocytic leukemia. The study will enroll 23 adults and monitor for …

This early-stage study is testing a new gene therapy called UB-VV400, alone and with the drug rapamycin, in 70 adults with relapsed or refractory large B-cell lymphoma. The main goals are to find safe doses and check for side effects. Researchers will also look for signs that the…

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

This study tests a new approach to prevent lymphoma from spreading to the brain in patients at high risk. Participants receive a stem cell transplant using drugs that better reach the brain. The goal is to see if this treatment is safe and feasible for 36 adults with newly diagno…

This study tests whether PET scans and blood tests for tumor DNA can help doctors adjust chemotherapy for people with early-stage diffuse large B-cell lymphoma (DLBCL). About 40 participants will receive standard R-CHOP treatment, and their response will be monitored with imaging…

This study is testing a new spinal fluid test that looks for tumor DNA in people with aggressive B-cell lymphoma who are at high risk for the cancer spreading to the brain. Researchers want to see how often this test finds signs of lymphoma that standard tests miss. About 50 part…

This study is a registry that will follow up to 8,000 people with chronic lymphocytic leukemia (CLL) and related blood cancers over many years. It does not test a new treatment but instead collects information on how patients are doing over time, including survival. The goal is t…